Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 18/20 | 0.69 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL9585856 | 0.96 | VCAM1 (0.69) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL809482 | 0.85 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL10452716 | 0.85 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL29780388 | 0.85 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL5452840 | 0.84 | VCAM1 (0.67) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL30430066 | 0.83 | VCAM1 (0.71) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL9323485 | 0.83 | VCAM1 (0.71) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL376610 | 0.83 | VCAM1 (0.71) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL1184879 | 0.81 | VCAM1 (1.00) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL3294854 | 0.81 | VCAM1 (0.69) | VCAM1NPBWR1MCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5500668-A | INK JET PRINTING | XEROX CORPORATION (US) | 1996-03-19 | — | — | US | claimed |
| CN-108997175-B | Method for preparing sodium m-nitrobenzenesulfonate and derivatives thereof by sulfonating chlorosulfonic acid | 金华双宏化工有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-2345636-B1 | CASR AGONIST | AJINOMOTO KK (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9174932-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9000208-B2 | Glutamate derivatives or salts thereof | AJINOMOTO CO., INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8877739-B2 | Prophylactic agent or therapeutic agent for diabetes or obesity | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20140303122-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8796485-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | AJINOMOTO CO., INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2554165-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | Ajinomoto Co., Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-5500668-A | INK JET PRINTING | XEROX CORPORATION (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0583748-A1 | Method for recovering oxygen from oxygen-containing gaseous mixtures | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1994-02-23 | — | — | EP | disclosed |
| EP-0066282-B2 | HEAT-DEVELOPABLE COLOR PHOTOGRAPHIC MATERIALS | FUJI PHOTO FILM CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
| US-4812382-A | BENZYLDIMETHYLALKYLAMMONIUM 3-NITRO-4-CHLOROBENZENESULFONATE | EASTMAN KODAK COMPANY (US) | 1989-03-14 | — | — | US | disclosed |
| US-4806283-A | Quaternary ammonium salts | EASTMAN KODAK COMPANY (US) | 1989-02-21 | — | — | US | disclosed |
| US-4705861-A | AZO DYE CHEMICAL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | disclosed |
| EP-0187231-A2 | Amino phenyl benzothiazoles | BAYER AG (DE) | 1986-07-16 | — | — | EP | disclosed |
| EP-0066282-B1 | HEAT-DEVELOPABLE COLOR PHOTOGRAPHIC MATERIALS | FUJI PHOTO FILM CO., LTD. (JP) | 1986-01-02 | — | — | EP | disclosed |
| US-4478927-A | SILVER HALIDE EMULSION, ORGANIC SILVER SALT, BINDER, AND DYE-RELEASING REDOX COMPOUND; PHOTOTHERMOGRAPHY; STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1984-10-23 | — | — | US | disclosed |
| EP-0066282-A1 | Heat-developable color photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1982-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303122-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | VCAM1 3457/4885NPBWR1 604/4885MCHR1 506/4885 |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | GPR119, GIPR, CASR | VCAM1 2465/4885NPBWR1 57/4885MCHR1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.